BS_MDBT7S5Z
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 26.741130091984232
- age_years
- 11.753
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.589
- MYC_TARGETS_V1+0.586
- G2M_CHECKPOINT+0.569
- MYC_TARGETS_V2+0.551
- OXIDATIVE_PHOSPHORYLATION+0.314
- PANCREAS_BETA_CELLS+0.265
- MITOTIC_SPINDLE+0.226
- UNFOLDED_PROTEIN_RESPONSE+0.219
- DNA_REPAIR+0.214
- ESTROGEN_RESPONSE_EARLY+0.163
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.504
- IL6_JAK_STAT3_SIGNALING-0.435
- ALLOGRAFT_REJECTION-0.419
- TNFA_SIGNALING_VIA_NFKB-0.372
- INFLAMMATORY_RESPONSE-0.371
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- APOPTOSIS-0.294
- P53_PATHWAY-0.284
- COMPLEMENT-0.261
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.908 |
| 2 | BS_74FS6GMW | ATRT | — | 0.900 |
| 3 | MNG164 | — | — | 0.891 |
| 4 | MNG592 | — | — | 0.888 |
| 5 | BS_KDSTG5YY | EPN | Posterior Fossa EPN | 0.885 |
| 6 | SRR8526717 | — | cohortMD1 | 0.884 |
| 7 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.884 |
| 8 | X7c81e3d9.c538.468a.8a2a.f34513bac230 | — | cohortA3 | 0.881 |
| 9 | SRR8518345 | — | E | 0.881 |
| 10 | MNG1194 | — | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.589 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.586 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.569 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.551 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.314 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.265 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.226 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.219 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.214 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.163 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.158 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.141 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.136 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.078 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.073 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.058 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.036 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.022 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.014 | Inavolisib | — uncovered |